Madhavi Bandi
0000-0002-7562-0170
Publication & Citation Trends
Most Cited Works
Publications
95 total
Abstract 4252: Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers
Cited by 0
Semantic Scholar
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumors.
Cited by 1
Semantic Scholar
Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer
Cited by 0
Semantic Scholar
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor.
Cited by 0
Semantic Scholar
Abstract B002: POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts
Cited by 1
Semantic Scholar
A duplexed high-throughput mass spectrometry assay for bifunctional POLB polymerase and lyase activity. OA
Cited by 3
Semantic Scholar
792 TNG917: a potent and orally active inhibitor of euchromatic histone lysine methyltransferases (EHMT1/2) for the treatment of immune-cold tumors OA
Cited by 1
Semantic Scholar
Abstract 3242: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors
Cited by 0
Semantic Scholar
Research Topics
Ubiquitin and proteasome pathways
(24)
PARP inhibition in cancer therapy
(21)
Cancer, Hypoxia, and Metabolism
(16)
Nuclear Structure and Function
(16)
Multiple Myeloma Research and Treatments
(11)
Frequent Co-Authors
Affiliations
Brigham and Women's Hospital
Merck & Co., Inc., Rahway, NJ, USA (United States)
The University of Texas MD Anderson Cancer Center
Harvard University
Pediatric Oncology Group